In the last trading session, 3.85 million shares of the Abbott Laboratories (NYSE:ABT) were traded, and its beta was 0.75. Most recently the company’s share price was $107.59, and it changed around $0.52 or 0.49% from the last close, which brings the market valuation of the company to $186.69B. ABT currently trades at a discount to its 52-week high of $121.64, offering almost -13.06% off that amount. The share price’s 52-week low was $89.67, which indicates that the current value has risen by an impressive 16.66% since then. We note from Abbott Laboratories’s average daily trading volume that its 3-month average coming to 5.92 million.
Abbott Laboratories stock received a consensus recommendation rating of Hold, based on a mean score of 1.81. If we narrow it down even further, the data shows that 0 out of 20 analysts rate the stock as a Sell; another 7 rate it as Overweight. Among the rest, 7 recommended ABT as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Abbott Laboratories is expected to report earnings per share of $1.04 for the current quarter.
Abbott Laboratories (NYSE:ABT) trade information
Instantly ABT has showed a green trend with a performance of 0.49% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently down -2.25% year-to-date, but still down -1.48% over the last five days. On the other hand, Abbott Laboratories (NYSE:ABT) is -2.70% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $130.77, which translates to bulls needing to increase their stock price by 17.73% from its current value. Analyst projections state that ABT is forecast to be at a low of $117 and a high of $150.
Abbott Laboratories (ABT) estimates and forecasts
Abbott Laboratories share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 11.17 percent over the past six months and at a 4.05% annual growth rate that is well below the industry average of 18.30%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -3.70% in revenue this quarter, and will report a decrease of -0.90% in the next quarter. The year-over-year growth rate is expected to be -2.40%, down from the previous year.
Consensus estimates provided by 17 financial analysts predict the company will bring in an average of $9.73 billion in revenue for the current quarter. 17 analysts expect Abbott Laboratories to make $9.91 billion in revenue for the quarter ending Sep 2024.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 19.65%. Abbott Laboratories earnings are expected to increase by 4.29% in 2024, but the outlook is positive 7.80% per year for the next five years.
ABT Dividends
Abbott Laboratories’s next quarterly earnings report is expected to be released in May. The annual dividend yield of the stock is 1.97 percent and its annual dividend per share was 2.12. It is important to note, however, that the 1.97% dividend yield ratio should be regarded as a guide only, as many other factors should be taken into consideration before making any investment decision.
